Revenue: As of FY2026 Q1, the actual value is USD 6.1 M.EPS: As of FY2026 Q1, the actual value is USD -0.09.EBIT: As of FY2026 Q1, the actual value is USD -1.136 M.<h3>Segment Revenue</h3><ul><li>Cross-border Freight Solutions: Revenue increased by $0.7 million, or 16.7%, from $4.1 million in Q3 2024 to $4.8 million in Q3 2025, primarily due to increased demand for cross-border airfreight solutions, despite a decrease in ocean freight revenue.</li><li>Pharmaceutical Distribution: This new segment generated $1.3 million in revenue for Q3 2025, with no comparable revenue in the prior year.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit: Increased by $0.6 million, or 112.2%, from $0.5 million in Q3 2024 to $1.1 million in Q3 2025. The gross margin for cross-border freight solutions decreased slightly to 11.8% from 12.8% in the prior year, while the pharmaceutical distribution segment achieved a gross margin of 40.9%.</li><li>Operating Expenses: Total operating expenses increased by $0.5 million, or 28.7%, from $1.9 million in Q3 2024 to $2.4 million in Q3 2025, driven by higher general and administrative expenses and the introduction of selling expenses related to the new pharmaceutical distribution segment.</li><li>Net Loss: The net loss was $1.4 million for Q3 2025, compared to $1.3 million in Q3 2024, reflecting increased operating expenses and interest expenses.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Net cash used in operating activities was - $4.0 million for Q3 2025, compared to - $1.4 million in Q3 2024, primarily due to increased working capital requirements and higher operating expenses.</li><li>Free Cash Flow: Not explicitly detailed, but implied negative due to operating cash flow and capital expenditures.</li></ul><h3>Unique Metrics</h3><ul><li>Revenue per Ton for Airfreight: Increased by $267, or 86.6%, to $576 per ton in Q3 2025, from $309 per ton in Q3 2024, due to stronger demand for value-added services.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company aims to expand its customer base and improve service quality to achieve sustainable growth. It plans to enhance its cross-border supply chain capabilities and expand its pharmaceutical distribution business.</li><li>Non-Core Business: The company is exploring strategic acquisitions and investments to diversify service offerings and expand global footprints.</li></ul>

Lakeside | 10-Q: FY2026 Q1 Revenue: USD 6.1 M